Conference Coverage

Subclinical hypothyroidism predicts cardiovascular mortality in NHANES


 

AT ACC 13

SAN FRANCISCO – Subclinical hypothyroidism is a strong independent predictor of cardiovascular mortality in a healthy population at baseline, a national study indicated.

Among 7,883 participants in the National Health and Nutrition Examination Survey III (NHANES III) who were over age 40 years and free of overt hyper- or hypothyroidism, 5.3% had subclinical hypothyroidism as defined by a thyroid-stimulating hormone level of 5-19.99 mIU/L and a thyroxine level of 5-12 mcg/dL. During a mean 12.3 years of follow-up, 25.2% of the subclinical hypothyroid group died of cardiovascular causes, compared with 16.9% of euthyroid controls, Dr. Tushar A. Tuliani reported at the annual meeting of the American College of Cardiology.

Similarly, death due specifically to ischemic heart disease occurred in 15.4% of the subjects with subclinical hypothyroidism, compared with 9.6% of euthyroid controls, added Dr. Tuliani of Wayne State University–Detroit Medical Center.

In a multivariate analysis that adjusted for standard cardiovascular risk factors and demographic variables, individuals with subclinical hypothyroidism had a 20% increased risk of all-cause mortality, a 24% increase in cardiovascular mortality, and a 34% increased risk of death from ischemic heart disease. All of these increases were statistically significant and clinically meaningful, he noted.

NHANES III is an in-depth weighted survey conducted by the Centers for Disease Control and Prevention in a nationally representative population.

Dr. Tuliani reported having no financial conflicts.

Recommended Reading

Oral Relaxin Improves Poststroke Recovery
MDedge Internal Medicine
Traumatic Brain Injury Linked to GH Deficiency
MDedge Internal Medicine
Resistant Hypothyroidism? Consider Adding Liothyronine
MDedge Internal Medicine
Calcium Protective Against Hyperparathyroidism
MDedge Internal Medicine
FDA Panel Backs Somatostatin Analogue for Cushing's
MDedge Internal Medicine
FDA Approves Second Drug for Rare Thyroid Cancer
MDedge Internal Medicine
Thyroid Hormone Replacement Benefits Subset of CKD Patients
MDedge Internal Medicine
FDA approves pasireotide for Cushing's, with postmarketing safety studies
MDedge Internal Medicine
Clinical guidelines for hypothyroidism 'take the middle ground' on TSH
MDedge Internal Medicine
Cancer deaths declined 20% since 1991
MDedge Internal Medicine